Pfizer-BioNTech begin Omicron vaccine trial
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday. Pfizer’s CEO Albert Bourla
AFP
Read More
Follow Us on Google News